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design of cancer therapeutics. Additionally the high degree of structural conservation within the
kinase superfamily often leads to inhibitors that exhibit little selectivity and substantial cross reac-
tivity. This work investigates the conformational changes that accompany the binding of Gleevec, or
imatinib mesylate, to the tyrosine kinases c-Kit and c-Abl. Our analysis is that this ﬁt is driven, at
least in part, by the need to exclude water from solvent-exposed backbone hydrogen bonds. Both
experimental and molecular modeling studies of the active state inhibitor of the tyrosine kinase
c-Abl indicate that solvent exclusion also plays a role in this system.
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Protein kinases have proven to be important targets for drug-
based cancer treatments. Targeting the tyrosine kinases that regu-
late cell growth and proliferation has yielded some of the most dra-
matic results to date, as witnessed by the success of imatinib
mesylate, or Gleevec, for the treatment of both chronic myeloid
leukemia (CML) [1] and gastrointestinal stromal tumors (GIST)
[2]. However this cross reactivity, mostly due to the high degree
of structural conservation with the kinase superfamiliy, is also fre-
quently linked to toxic side effects [3]. The conformational ﬂexibil-
ity exhibited by these proteins, most evident in the dramatic
structural changes that accompany the conversion from the inac-
tive to the active state, poses additional challenges to the design
of cancer therapeutics as witnessed by the emergence of both
imatinib-resistant CML and GIST [4]. Further complicating the ra-
tional design process is the observation that the kinase variants ob-
served in patients who have developed resistance to imatinib can
differ markedly, in residue type and domain location, depending
on whether the patient is being treated for CML [5] or a GIST [6].
Two recent reviews highlight the myriad challenges faced bychemical Societies. Published by Eresearchers in the design of potent and selective kinase inhibitors
[7,8].
CML is characterized by increased, and unregulated, production
of myeloid cells. This proliferation is caused by improper activa-
tion of the Abelson tyrosine kinase (c-Abl) through the formation
of a chimeric protein, bcr-Abl, in turn caused by a genetic translo-
cation that results in the fusion of the breakpoint cluster (bcr) gene
with the c-Abl gene. Whereas under normal conditions the intra-
cellular c-Abl kinase exists in a regulated state with very low activ-
ity, fusion of the kinase domain of c-Abl with bcr produces a 190–
210 kDa constitutively active protein that drives leukemia patho-
genesis through phosphorylation and activation of a range of
downstream proteins. The recognition of the inactive conforma-
tion of Abl, or bcr-Abl since the kinase domains of bcr-Abl and c-
Abl are identical in sequence, by imatinib mesylate allows it to
bind in a pocket close to the ATP-binding site and prevent bcr-
Abl activation by restricting the motion of the so-called activation
loop [9].
GIST, the most common mesenchymal tumors of the gastroin-
testinal tract, have historically been extremely unresponsive to
chemotherapy. Oncogenic mutations in the cytokine receptor tyro-
sine kinase c-Kit are implicated in the pathogenesis of the vast
majority of all GIST, as well as being associated with other condi-
tions such as mast cell leukemia and acute myeloid leukemia
(AML). c-Kit plays a central role in mast cell differentiation,lsevier B.V. All rights reserved.
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tions only becomes active after autophosphorylation of speciﬁc
tyrosine residues. This activation is the result of homodimerization
of c-Kit, which occurs in response to the attachment of a cytokine
stem cell factor (SCF) to two of the extracellular domains. Imatinib
mesylate binds to the inactive state of c-Kit and, as with bcr-Abl,
inhibits the motion of the activation loop that is necessary for
the binding of ATP and thus required for activation of the enzyme
[10].
The global movement of c-Kit that accompanies activation in-
volves a near seven degree tilt of the N-lobe of the protein towards
the C-lobe (Fig. 1A). This is accompanied by a switch of the activa-
tion loop from a closed conformation (Fig. 1C), with the DFG motif
out, to an open conformation with the DFG motif in (Fig. 1D). The P
loop also undergoes a conformational change that facilitates the
binding of ATP in the active state, and as can be seen from
Fig. 1C and D, the C-helix also undergoes a conformational shift.
In addition the binding of imatinib also induces a readjustment
of the so-called DFG motif within the activation loop due to a steric
clash between the inhibitor and the Phe811 residue (Fig. 1B) [10].
Whereas the position of the Glu640 residue remains oriented to-
wards the inside of the protein in both the inactive (1T45) and ac-
tive (1PKG) state of c-Kit, recent crystal structures for a variety of
c-Abl ligand-bound complexes [11] indicate that c-Abl is capable
of adopting a conformation where the C-helix undergoes a more
radical shift that ﬂips this Glu, residue 305 in c-Abl (1OPJ), out to-
wards the exterior of the protein. In addition, crystal structures
were also obtained of an inactive form of c-Abl with the DFG motifFig. 1. (A) Activation of c-Kit involves a 6.7 tilt on the N-lobe towards the C-lobe, show
yellow). (B) The induced ﬁt of imanitib mesylate to c-Kit, shown as a superimposition of
Kit + inhibitor (1T46, gray). (C) Key structural elements of 1T45: the juxtamembrane regio
C-loop in gray and the activation or A-loop in red. (D) Key structural elements of 1PKG w
the control C–helix in cyan, the catalytic or C-loop in gray and the activation or A-loopin, allowing for the possibility that c-Abl is capable of adopting sev-
eral distinctly different inactive conformations.
A comparison of the crystal structures of seven unphosphory-
lated pathogenic mutants of the tyrosine kinase FGFR2K with those
of the phosphorylated and unphosphorylated wild-type kinase has
identiﬁed another kinase region that is implicated in the pathogen-
esis of tyrosine kinases [12]. The residues that comprise this
‘‘molecular brake” are conserved over a wide range of kinases,
including c-Kit, and are comprised of a triad of Asn, Glu and Lys
(Asn655, Glu671 and Lys807 in c-Kit). The Asn is at the end of the
b4 loop (see Fig. 2A–D), a short sequence that connects the C-helix
to the b4 strand, the Glu is at the end of a kinase hinge region, and
the Lys is part of the b8 strand (see Fig. 5) that connects directly to
the A-loop (Fig. 2A–D). It is postulated that this NEK triad modu-
lates a molecular brake that allows for interaction between the ki-
nase hinge, the C-helix and the A-loop that in turn is used to
control tyrosine kinase activity. Speciﬁcally the conformation with
this molecular brake on, as identiﬁed by the hydrogen bonding pat-
tern described in Fig. 2B, maintains the A-loop, and the kinase, in
the inactive conformation by inhibiting the movement of the N-
lobe towards the C-lobe. Releasing the brake, as evidenced by the
weakened hydrogen bonding pattern in Fig. 2C, allows for this glo-
bal movement and conversion of the enzyme to the active state.
Mutations that remove the hydrogen bonds within the molecular
brake are implicated in the pathogenesis of a range of skeletal
and cancer disorders known to be caused by the activation of var-
ious tyrosine kinases [13]. Mutations that strengthen the interac-
tions between the C-helix and the A-loop, are also shown ton as a superimposition of the active form (1PKG, blue) and the inactive form (1T45,
the inactive form in the absence of inhibitor (1T45, yellow) and the structure of c-
n colored in green, the P loop in magenta, the control C-helix in cyan, the catalytic or
ith ADP bound: the juxtamembrane region colored in green, the P loop in magenta,
in red.
Fig. 2. (A) The molecular brake is circled and includes the kinase hinge, the b4 loop and the b8 strand, for the inactive form of c-Kit (1T45, yellow) and the active form (1PKG,
blue). (B) An expansion of the molecular brake to show the hydrogen bonds present in the conformation with the brake on (1T45). (C) An expansion of the molecular brake to
show the hydrogen bonds lost in the conformation with the brake off (1PKG). (D) The molecular brake region for c-Kit with bound imatinib mesylate (1T46). (E) The molecular
brake off for the hinge region of inactive c-Abl + imatinib mesylate (1OPJ).
E.F. Healy et al. / FEBS Letters 583 (2009) 2899–2906 2901indirectly weaken this molecular brake and thereby shift equilib-
rium in favor of the active state. These changes also correlate with
known tyrosine kinase-related diseases [14].
The hydrogen bonding pattern observed when the molecular
brake is assumed to be engaged in the inactive state of c-Kit
(1T45, Fig. 2B) is comparable to that reported for the unphosphor-
ylated wild-type structure of FGFR2K. This hydrogen-bonded net-
work, mediated by the NEK triad, is substantially weakened inthe active form of c-Kit (1PKG, Fig. 2C) mirroring what was found
for both phosphorylated FGFR2K and mutant variants [12]. The
binding of imatinib mesylate to c-Kit induces a small but meaning-
ful conformational shift of both the activation loop and the C-helix
(Fig. 1B). Inspection of the molecular brake region of the structure
for c-Kit with bound inhibitor (1T46) yields the surprising result
that the binding of imatinib mesylate to the inactive form of c-
Kit actually weakens this molecular brake (Fig. 2D). This result is
2902 E.F. Healy et al. / FEBS Letters 583 (2009) 2899–2906reminiscent of how the co-crystal structure of ligand-bound c-Kit
revealed that the bound inhibitor displaces the juxtramembrane
domain that is responsible for maintaining the enzyme in the
autoinhibitory state [10].
The idea that excluding solvent from protein regions containing
exposed hydrogen bonds can be a determinant factor in ligand–
protein interactions and protein–protein interactions has been pre-
viously proposed [15]. Indeed a screening protocol that identiﬁes
such structural vulnerabilities, or dehydrons, has been developed
[16], and used to guide the rational development of a more selec-
tive variant of imatinib mesylate [17]. We wanted to investigate
the possibility that such solvent exclusion from the b4 loop-C-helix
region of c-Kit might be the underlying causative agent for the re-
lease of the aforementioned ‘‘molecular brake. A potential role for
solvent exclusion in the binding of other inhibitors, speciﬁcally the
substituted ellipticines, is also investigated.2. Materials and methods
2.1. Kinase assay
A ﬂuorescence-based tyrosine kinase assay was utilized to
determine the 50% inhibitory concentrations (IC50) of 9-hydroxy-
elipticine hydrochloride and 9-methoxy-2-methyellipticinium ace-
tate against puriﬁed N-terminal His6-tagged recombinant human
Abl kinase expressed by baculovirus in Sf21 insect cells.Table 1
Consensus scores for the docking of imatinib mesylate to c-Kit, to the artiﬁcally
constrained c-Kit with the NEK brake ‘‘on”, and to c-Abl.
Protein LigScore1 LigScore2 Energy PMF PMF04
1T46 6.1 8.6 46.2 184 80
1T46 (brake on) 6.1 8.6 46.4 179 77
1OPJ 6.6 8.8 47.9 185 89
Fig. 3. (A) Solvent accessible surface for residue Ile653 and the ligand in 1T46. (B) Solve
1T46. (C) Surface representation of the active site of 1T46 with the Ile653 side chain col
exposed backbone hydrogen bond between Leu644 and Gly648, with the inactive c-Kit in2.2. Docking
Crystal structures for imatinib mesylate bound to c-Kit (1T46)
[10], ligand-bound c-Abl (1OPJ) [18] as well as for the inactive
(1T45) [10] and active (1PKG) [19] forms of c-Kit are available from
the Research Collaboratory for Structural Bioinformatics (RCSB)
protein data bank (www.rcsb.org). Ligands were docked using
CDOCKER [20] and the ﬁt evaluated using a consensus scoring
scheme. For the docking of ellipticine and its methylated derivative
to c-Abl the structure for pdb entry 1OPKwas used [18]. A shape-di-
rected dockingmethodology, LigandFit [21], was employed to iden-
tify potential c-Abl binding sites. The estimation of free energy of
non-covalent complex formation from a protein and a ligand is
based on the assumption that DGbinding = Gcomplex  Gprotein 
Gligand, with the Poisson Boltzmann Surface-Area (PBSA) [22]
utilized as the implicit solvent model.
2.3. Molecular dynamics
Molecular dynamic (MD) simulations were performed starting
from the crystal structure of the wild-type kinase complexed with
imatinib mesylate, (1T46). After immersion in an orthorhombic cell
of TIP3P explicit water molecules, neutralization with counterions,
the system was minimized and then heated to 300 K. After equili-
briation for 6 ns the resulting structures were the starting point of
the production 1 ns MD simulations. Movies for the MD simula-
tion, with and without bound ligand, are available for download
in the Supplementary data.
2.4. Quantum mechanics
A model structure for the peptide sequence corresponding to
residues 650–655 of the b4 loop of c-Kit was generated from the
coordinates of PDB entry 1T46 and a potential energy surface
was calculated for rotation around the Ca–Cb bond of the Ile653
residue using the AM1 Hamiltonian [23] with water as solvent,
as implemented in the conductor-like screening model (COSMO)
[24].nt accessible surface for residue Ile653 and the ligand in our artiﬁcially constrained
ored in red. (D) Induced ﬁt of imanitib mesylate to c-Kit in relation to the solvent-
the absence of inhibitor in yellow (1T45) and c-Kit + inhibitor in gray (1T46).
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Human protein tyrosine kinase sequences, c-Kit (P10721), c-Abl
(P00519) and FGFR2 (P21802), were obtained from the UniProt
database. Multiple sequence alignments of the catalytic kinase do-
mains were created using ProbCons [25]. Proteins were aligned and
superimposed using the MODELER protocol as implemented in the
Discovery Studio program suite from Accelrys Inc.
Full details of all the methodologies, along with download infor-
mation for the MD simulations, are available in the Supplementary
data.
3. Results and discussion
3.1. Imatinib mesylate
Based on the pattern of activating mutations it was concluded
that the hydrogen bonds between the Asn of the NEK triad and
the backbone atoms of the b4 loop were the most critical constitu-
ents of the brake. As Fig. 2C demonstrates, these are the very
hydrogen bonds that are broken when the Asn655 side chain swings
out, and in this analysis results in disengaging the brake to form
the active conformation of c-Kit (1PKG). To probe the nature of this
conformational change the side chains of the residues in the b4
loop of the ligand-bound form of c-Kit, 1T46, were rotated to gen-
erate a structure for PDB entry 1T46 with the molecular brake on.
Imatinib mesylate was then docked to this constrained conformer
(‘‘1T46-brake on”, Table 1) and the scores for the docking solutionFig. 4. (A) Trajectory analysis for the intra-helix backbone hydrogen bond distance betwe
( ) and without ( ) bound ligand. (B) Final conformation for the 1 ns MD run for c-
bound ligand. (links to the movies depicting the complete MD production runs for eachcompared with that obtained using the original 1T46 structure. The
consensus docking scores given in Table 1 indicate no preference
for either conformation.
Apart from the rotation of the Asn side chain one of the most
dramatic conformational changes induced by the binding of imati-
nib mesylate is a rotation of the Ile653 side chain by approx 120.
Conformational analysis of a model system of residues 650–655
of structure 1T46, using the AM1 Hamiltonian, for rotation around
the Ca–Cb bond of the Ile653 side chain (Fig. 2D) indicated that this
conformation represents a local energy minimum, more stable
by1.5 kcal mol1. Since the impetus for such a conformational shift
cannot be due to a steric clash, and since no energetic beneﬁt is re-
ﬂected in near identical scoring function values obtained for the
two docking solutions, we compared the solvent accessible sur-
faces for residue Ile653 and the ligand in both 1T46 and our artiﬁ-
cially constrained 1T46 clearly identiﬁes the impact of this Ca–Cb
bond rotation for the Ile653 (Fig. 3A and B). Rotation of the side
chain provides for solvent exclusion from that region of the protein
bounded by the b4 loop, the C-helix and the ligand. A surface rep-
resentation of the active site of 1T46 with the Ile653 side chain col-
ored in red (Fig. 3C) further illustrates this hydrophobic contact.
The beneﬁt of such solvent exclusion can be traced to the presence
of an intra-helix backbone hydrogen bond between Leu644 and
Gly648 of the C-helix (Fig. 3D). Exposure to the aqueous environ-
ment would serve to weaken this interaction, thus destabilizing
the C-helix. Solvent exclusion therefore stabilizes the secondary
structure. Indeed six such solvent-exposed intramolecular back-
bone hydrogen bonds, or dehydrons, have been previously identi-en Leu644 and Gly648 of the C-helix for a 1 ns molecular dynamics run for c-Kit with
Kit with bound ligand. (C) Final conformation for the 1 ns MD run for c-Kit without
simulation can be found in the Supplementary data).
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Kit structure [26], including the hydrogen bond shown in Fig. 3D.
To test this thesis we performed 1 ns Molecular dynamics (MD)
simulations, in a truncated orthorhombic cell of TIP3P explicit
water molecules, on pre-minimized, pre-equilibriated (6 ns) c-Kit
structures with and without bound ligand. Trajectory analysis for
the backbone hydrogen bond between the carbonyl of the Leu644
and the amide of the Gly648 (Fig. 4A) shows a trendline that pre-
dicts the progressive weakening of the hydrogen bond to a median
value of 2.14 Å over the ﬁnal 100 ps of the simulation with ligand,
versus a median value of 1.95 Å without ligand. The ﬁnal frame
from the simulation with bound ligand in Fig. 4B clearly identiﬁes
the close contact between the ligand, the Cb-Me group of Ile653 and
the Leu644 side chain that serves to exclude solvent from the C-he-
lix. As shown in Fig. 4C the absence of the ligand results in a rota-
tion of the Leu644 side chain that further exposes the vulnerable
backbone hydrogen bond to the destabilizing inﬂuence of the sur-
rounding water molecules.
The sequence alignments shown in Fig. 5 indicate that the NEK
molecular brake triad found in FGFR2K and c-Kit becomes a QEK
brake in c-Abl, with the conserved change of an Asn to a Gln at
the end of the b4 loop. As can be seen in Fig. 2E, if such a brake
is operative in the inactive form of c-Abl any such inhibition of
the N to C-lobe movement is removed with the binding of imatinibFig. 5. Sequence homology for FGFR2mesylate. However, closer inspection of the b4 loop residues of c-
Abl reveals that the increased rotational freedom, due to the addi-
tional methylene provided by the Asn655 to Gln319 substitution,
would mitigate against the formation of a hydrogen-bonded net-
work between the Gln319 side chain and residues His314, Glu335
and Lys397. Furthermore, due to the lack of a methyl group at the
a-carbon of the Leu317 side chain rotation around the Ca–Cb bond
would no longer provide a hydrophobic contact leading to solvent
exclusion from the region bounded by the b4 loop and the C-helix.
If dehydration of an otherwise exposed backbone hydrogen bond is
indeed the driving force for any ligand-induced conformational
change in this region of the protein then it would be predicted that
no brake release would accompany the binding of imatinib mesy-
late to c-Abl, if indeed any such molecular brake was present in the
ﬁrst case.
3.2. Ellipticine derivatives
Ellipticine derivatives (Fig. 6A) have been shown to possess
tyrosine kinase-inhibiting activity [27]. Kinetic assays of the 9-
hydroxyellipticene derivative with c-Kit, ﬁbroblast growth factor
receptor 3 (FGFR3) and t platelet derived growth factor (PDGFR-
a) demonstrated that inhibition was competitive with ATP and
exhibited little or no selectivity across the kinases [27]. The mostK, c-Kit (1T45) and c-Abl (1OPJ).
Fig. 6. (A) Inhibition of c-Kit through the binding of 9-hydroxy ellipticine. (B) Inhibition of c-Abl through the binding of 9-hydroxy ellipticine. (C) Docked structures for 9-
hydroxy ellipticene in blue, 9-methoxyellipticine in green and ADP in gray with 1OPK. (D) Position of the 9-methoxyellipticine ligand in relation to the backbone hydrogen
bond between Phe401 and Leu403.
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molecular modeling of the inhibitor with a D816V mutant of c-
Kit identiﬁed both a donor and acceptor hydrogen bond between
the –OH group at position 9 and key residues in the ATP-binding
pocket (Fig. 6A). Molecular dynamics conﬁrmed that the D816V
point mutation favors the active conformation, explaining why
the ATP-competitive binding mode of the ellipticines allows them
to maintain their potency against the c-Kit mutant while imatinib
mesylate is at least 100 times less active against the D816V variant.
The c-Kit inibition study found an IC50 of 0.4 lM for the 9-hydroxy
substituent, and only a slightly less efﬁcient value of 0.6 lM for the
9-methoxyellipticine, even though this substitution results in the
loss of a ligand–protein hydrogen bond. One possible explanation
for these near-equivalent inhibition values could be that the great-
er effectiveness of the methoxy substituent in excluding solvent
from the DFG region of the protein compensates for the loss of
the hydrogen bond.
Since 9-hydroxyellipticine was found to have little kinase selec-
tivity we decided to study its inhibition, along with that for the 9-
methoxy derivative, of c-Abl. Table 2 summarizes the observed IC50
and the calculated DGbinding for both ligands. The measured IC50 for
the inhibition of c-Abl by 9-hydroxyellipticine is similar to the re-
ported value for c-Kit, and the ligand binding mode is essentially
identical (Fig. 6B). The competitive character of the inhibition can
be seen from the superimposed docked structures for both deriva-
tives and ATP (Fig. 6C). While the experimental methodology only
yielded an approximate IC50 for the 9-methoxy derivative, the cal-Table 2
Calculated DG values and experimental IC50 values for the binding of 9-hydroxy-elipticine
Inhibitor Protein DFG
9-Hydroxy-elipticine 1OPK Out
9-Methoxy-2-methyellipticinium 1OPK Outculated DGbinding does indicate that, similar to the c-Kit result, the
absence of a ligand–protein donor–acceptor hydrogen bond still
leaves a fairly potent inhibitor. Inspection of the binding mode
for the 9-methoxy substituent with c-Abl (1OPK in Fig. 6D) yields
a possible explanation. Hydrophobic contact between the –OMe
methyl group and the Phe401 side chain allows for the exclusion
of solvent from a region that contains a backbone hydrogen bond
between Phe401 and Leu403. A comparable exposed hydrogen bond,
or dehydron, has been identiﬁed for c-Kit (1T46) [26], in this case
between Phe811 and Ala814. which also can be used to explain the
relatively low IC50 values observed for the inhibition of both
wild-type and D816V mutant forms of c-Kit by 9-methoxy deriva-
tive of ellipticine.
It has already been observed that molecular dynamics simula-
tions on the timescale necessary to follow the dramatic conforma-
tional changes that accompany activation of tyrosine kinases are
not practicable with current technologies [28]. However more lim-
ited dynamics simulations, together with crystallographic and
mutagenic studies, have produced a fairly consistent and reliable
picture of the current conformational landscape. Ligand binding
studies, such as those presented here, can also serve to complete
this picture by linking structural change to underlying instabilities
or defects in the macromolecular structure.
The results presented here indicate that solvent exclusion from
the b4 loop-C-helix region of c-Kit plays a role in both ligand bind-
ing to the inactive form and in the conformational change that
accompanies c-Kit activation, while solvent exclusion from the re-and 9-methoxy-2-methyellipticinium to c-Abl.
Glu305 DG (kcal mol1) IC50 (lM)
In 10.0 0.2
In 8.4 >1
2906 E.F. Healy et al. / FEBS Letters 583 (2009) 2899–2906gion surrounding the DFG motif also plays a role in ligand binding
to c-Abl. While it is impossible to determine the extent to which
such desolvation drives the various conformational changes, these
results do indicate that analyzing conformational dynamics in light
of these structural deﬁciencies can be of both explanatory and pre-
dictive value.
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